Abstract
A new series of p-tertbutylcalix[4]arenes integrated with isomer trifluoromethyl anilines has been designed as potential anticancer agents. The integration of trifluoromethyl anilines to p-tertbutylcalix[4]arene allows the access of C4, C5, C6, C10, C11 and C12 analogues in good yields (more than 85%). To evaluate the antiproliferative activity of the prepared derivatives, the cancer cell growth inhibition assays have been performed for three cancer cell lines (HeLa, A549, MCF-7, Hep-2) and kidney normal epithelial cells (Vero). The compounds including CF3 groups at ortho position (C4 and C10) show 25 and 12 fold higher antiproliferative activity against MCF-7 cells over Vero cells, respectively. Also, C6 and C12 show 11 and 8 fold higher antiproliferative activity against HeLa cells over Vero, respectively. These results highlight that new calixarene derivates can be worthy of further studies as potential anticancer agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
